Costs of pharmacotherapy of somatic co-morbidities in dementia patients in family practices;Kosten der pharmakotherapie internistischer komorbiditäten bei patienten mit demenz in der hausarztpraxis

Zeitschrift fur Allgemeinmedizin

Volumn 83, Issue 10, 2007, Pages 411-416

  Wagner, Gabriela ^a   Icks, A ^b   Abholz, H H ^a   Schroder Bernhardi D ^c   Rathmann, W ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Deutsches Diabetes Institut Düsseldorf   (Germany)

^c IQVIA   (United States)

Author keywords

Co morbidities; Costs; Dementia; General practice; Pharmacotherapy

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NEUROLEPTIC AGENT; NOOTROPIC AGENT; ORAL ANTIDIABETIC AGENT; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; DATA BASE; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; GENERAL PRACTICE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; RANK SUM TEST;

EID: 36049018031     PISSN: 09376801     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-990279     Document Type: Article

References (13)

1. Dormiswamy PM, Leon J, Cummings J, et al. Prevalence and impact of medical co-morbidity in Alzheimer's disease. Journal of Gerontology 2002; 57 A: M173-M177
2. Eaker ED, Mickel SF, Chyon P-H, et al. Alzheimer's disease or other dementias and medical care utilization. Annals of Epidemiology 2002; 12: 39-45
3. Fillit H, Hill J. The economic benefits of Acetylcholinesterase inhibitors for patients with Alzheimer's disease and associated dementias. Alzheimer Disease and Associated Disorders 2004; 18: 24-S29
4. Fishman P, Korff M Von, Lozano M, et al. Chronic care costs in managed care. Health Affairs 1997; 16: 239-247
5. Gambassi G, Landi F, Lapane KL, et al. Is drug use by elderly with cognitive impairment influenced by type of dementia? Pharmacotherapy 1999; 19: 430-436
6. Guttermann EM, Markowitz JS, Lewis B, et al. Costs of Alzheimer's disease and related dementia in Managed-Medicare. Journal of the American Geriatric Society 1999; 47: 1065-1071
7. Kaduszkiewicz H, Wiese B, Bussche H van den. Die Versorgung Demenzkranker aus Sicht niedergelassener Haus-und Gebietsärzte-Ergebnisse einer empirischen Untersuchung. Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswesen 2007; 101: 15-20
8. Kales HC, Blow FC, Copeland LA, Bingham RC, et al. Health care utilization by older patients with coexisting dementia and depression. American Journal of Psychiatry 1999; 156: 550-556
9. Kirschstein R. Disease specific estimates of direct and indirect costs of illness and NIH support. National Institutes of Health June ; www.odnih.gov/osp/ospp/enastudies/cor
10. Kunik ME, Cully JA, Snow AL, Souchek J, et al. Treatable co-morbid conditions and use of VA Health Care services among patients with dementia. Psychiatric Services 2005; 56: 70-75
11. Löppönen MK, Isoaho RE, Räikä IJ, et al. Undiagnosed diseases in patients with dementia-a potential target group for intervention. Dementia and Cognitive Disorder 2004; 18: 321-329
12. Rathmann W. Arzneimittelverordnungen und Kosten bei diabetischer Polyneuropathie. Deutsche Medizinische Wochenschrift 2000; 125: 68-74
13. Schubert I, Küpper-Nybelen J, Ihle P, et al. Inanspruchnahme von Demenzpatienten im Spiegel von GKV-Daten. Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswesen 2007; 101: 7-13